Restrictive fluid therapy and high-dose vitamin C in sepsis

Nature Reviews Nephrology, Published online: 01 August 2022; doi:10.1038/s41581-022-00609-5Two recent randomized trials provide evidence to guide the management of sepsis. The CLASSIC trial reports that restrictive fluid therapy has no mortality benefit compared to a standard regimen in patients with septic shock, whereas the LOVIT trial reports that high-dose intravenous vitamin C might be harmful in patients with severe sepsis.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Source Type: research